open access

Vol 49, No 2 (2018)
REVIEW ARTICLE
Published online: 2018-08-30
Submitted: 2017-10-24
Get Citation

Combination Therapies of Hypomethylating Agents for Elderly Patients with Acute Myeloid Leukemia

Jiayu Huang, Yun Lian, Sixuan Qian
DOI: 10.2478/ahp-2018-0011
·
Acta Haematol Pol 2018;49(2):59-64.

open access

Vol 49, No 2 (2018)
REVIEW ARTICLE
Published online: 2018-08-30
Submitted: 2017-10-24

Abstract

Older patients with acute myeloid leukemia (AML) are encumbered with poor long-term outcomes due to patient and disease characteristics. Hypomethylating agents (HMAs), acting as DNA methyltransferase (DNMT) inhibitors, have been established as a new treatment option, but they have been associated with relatively low response rates (15%–20% complete remission) when administered separately for treating elderly with AML. However, appropriate combination therapies with decitabine or azacitidine have flourished. The results of randomized trials of various combinations of HMAs with chemotherapy, histone deacetylase inhibitors, monoclonal antibodies, immunomodulatory agents, kinase inhibitors, or bexarotene are summarized.

Abstract

Older patients with acute myeloid leukemia (AML) are encumbered with poor long-term outcomes due to patient and disease characteristics. Hypomethylating agents (HMAs), acting as DNA methyltransferase (DNMT) inhibitors, have been established as a new treatment option, but they have been associated with relatively low response rates (15%–20% complete remission) when administered separately for treating elderly with AML. However, appropriate combination therapies with decitabine or azacitidine have flourished. The results of randomized trials of various combinations of HMAs with chemotherapy, histone deacetylase inhibitors, monoclonal antibodies, immunomodulatory agents, kinase inhibitors, or bexarotene are summarized.

Get Citation

Keywords

acute myeloid leukemia; elderly; azacitidine; decitabine; combination therapies

About this article
Title

Combination Therapies of Hypomethylating Agents for Elderly Patients with Acute Myeloid Leukemia

Journal

Acta Haematologica Polonica

Issue

Vol 49, No 2 (2018)

Pages

59-64

Published online

2018-08-30

DOI

10.2478/ahp-2018-0011

Bibliographic record

Acta Haematol Pol 2018;49(2):59-64.

Keywords

acute myeloid leukemia
elderly
azacitidine
decitabine
combination therapies

Authors

Jiayu Huang
Yun Lian
Sixuan Qian

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl